13 June 2022
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Board and Management Change
Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces that Eleanor Brown has resigned for personal reasons. Ms Brown will be stepping down from the Board and her role as Chief Financial Officer with immediate effect and will leave the Group on 28 December 2022. Jenny Cutler has joined the Company as Interim Chief Financial Officer and a search for a permanent successor has begun.
Jenny is a Chartered Accountant (FCA) with over 20 years of finance leadership experience and has worked at AIM and Main Listed business. Most recently, Jenny was Chief Financial Officer of Fulcrum Utility Services Limited (AIM) and was previously Director of Finance and Interim Finance Director at Harworth Group plc (Main Market (premium)).
Dr Arron Tolley, Chief Executive Officer, commented: " Aptamer Group is grateful to Eleanor for her four years of service during which time the Company has grown significantly, become revenue generating and, at the end of 2021, was successfully admitted to AIM raising gross proceeds of £10.8 million, a process which Eleanor was central to. On behalf of the Company, I wish Eleanor well in her future endeavours."
"I am also pleased to welcome Jenny Cutler to the Company as Interim Chief Financial Officer. Jenny is a highly accomplished and experienced finance executive who has worked in interim and permanent roles in a variety of listed businesses. Jenny is well equipped to fulfil the role while a permanent successor is appointed, and I look forward to working with her. "
For further information, please contact:
Aptamer Group plc
Dr Arron Tolley +44 (0) 1904 56 7790
SPARK Advisory Partners Limited - Nominated Adviser
Andrew Emmott +44 (0) 20 3368 3550
Liberum Capital Limited - Broker
Richard Lindley / Ben Cryer / Will Hall / Cara Murphy +44 (0) 20 3100 2000
Consilium Strategic Communications
Matthew Neal / Chris Welsh / Lucy Featherstone +44 (0) 20 3709 5700
aptamergroup@consilium-comms.com
About Aptamer Group plc
Aptamer Group develops custom affinity binders through its proprietary Optimer® platform to enable new approaches in therapeutics, diagnostics and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers through the use of its proprietary Optimer platform.
Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global antibody market is currently worth over $145.0 billion. Optimer binders are engineered to address many of the issues found with alternative affinity molecules, such as antibodies, and offer new, innovative solutions to bioprocessing, diagnostic and pharmaceutical scientists.
Aptamer Group has successfully delivered projects for global pharma companies, diagnostic development companies, and research institutes covering a range of targets and applications with the objective of establishing royalty-bearing licenses. Through the unique Optimer technology and processes, scientists and collaborators are enabled to make faster, more informed decisions that support discovery and development across the Life Sciences.